openPR Logo
Press release

Global Dilated Cardiomyopathy Therapeutics Market: Increasing Prevalence of Congestive Heart Failure Fuels Growth, finds TMR

08-14-2017 06:16 PM CET | Health & Medicine

Press release from: Transparency Market Research

Global Dilated Cardiomyopathy Therapeutics Market:

Transparency Market Research in a recent publication says competition in the global dilated cardiomyopathy therapeutics market is expected to grow as prominent companies strive to develop effective drugs for the treatment of dilated cardiomyopathy. For example, in February 2017, Myokardia Inc., a biopharmaceutical company, announced first time administer of MYK-491 to a batch of healthy subjects. MYK-491 is a treatment for dilated cardiomyopathy which is in Phase 1.

Keen players in the market are also focusing on collaborations, mergers, and acquisitions to consolidate their position. For example, in January 2015, Array BioPharma announced its plans of acquiring and obtaining world rights to encorafenib, which is a late stage oncology product from Novartis Pharma AG.

 View Report @ http://www.transparencymarketresearch.com/dilated-cardiomyopathy-market.html

As per estimates by Transparency Market Research, the global dilated cardiomyopathy therapeutics market will be worth US$328.6 mn by the end of 2020 vis-à-vis revenue, expanding at a CAGR of 4.6% from 2014 to 2020.

Growing Incidence of Cardiac Diseases to Catapult Asia Pacific to Lead Position

The segment of angiotensin II receptor blockers led amongst other drug class segments in 2013. This was followed by the segment of beta blockers. The high acceptance of angiotensin II receptor blocks is attributed to their effective therapeutic action for the treatment of dilated cardiomyopathy.

Geography-wise, the report segments the global dilated cardiomyopathy therapeutics market into: North America, Asia Pacific, Europe, and Rest of the World. North America stood as the leading regional market in 2013 mainly due to high incidence of cardiac diseases. Asia Pacific is expected to take the lead in the upcoming years as changing lifestyle resulting in increasing incidence of cardiac diseases propels growth of dilated cardiomyopathy therapeutics market.

Efforts to Develop Specific Drugs for Dilated Cardiomyopathy Propels Growth

The alarming rise in the prevalence of congestive heart failure is one of the prominent growth drivers of the global dilated cardiomyopathy market. Dilated cardiomyopathy accounts for 30-40% of total number of congestive heart failures each year. As per statistics of the World Health Organization, 17.5 million deaths in 2013 were related to heart disorders. The increasing incidence of congestive heart diseases has created an urgent need for effective drugs and treatment, thereby benefitting the dilated cardiomyopathy therapeutics market.

Get accurate market forecast and analysis on the Dilated Cardiomyopathy Therapeutics Market [Drug Class Market. Request a sample to stay abreast on the key trends impacting this market.

http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2293

Due to this, several companies have initiated to carry out clinical trials so as to develop drugs specifically for dilated cardiomyopathy. At present, there is not a single FDA approved drug specifically for dilated cardiomyopathy because of which treatment administered is the same as that for congestive heart failure. For example, Array BioPharma is carrying out phase II study for its drug ARRY-371797 for the treatment of dilated cardiomyopathy. In addition, in 2014, Celladon Corporation completed its phase II study of MYDICAR to be used for the treatment of dilated cardiomyopathy. Success of these clinical trials will positively influence the global dilated cardiomyopathy therapeutics market.

Studies reveal that angiotensin receptor blockers such as valsartan can reduce probability of hospitalization by 28%. These drugs have also been effective for patients of systolic heart disease by reduction of deaths by 37% and also for reduced frequency of hospitalization. These factors are furthering the expansion of the global dilated cardiomyopathy therapeutics market.

On the flip side, the side effects of dilated cardiomyopathy therapeutics is leading to their declined use. Moreover, availability of implantable devices and promising gene therapy are acting as roadblocks to the market.

The review presented here is based on the findings of a report by Transparency Market Research, titled “Dilated Cardiomyopathy Therapeutics Market (Drug Class - Aldosterone Antagonists, Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs) and Beta-Blockers; Pipeline Drugs - ixCELL-DCM, ARRY-797, OR-1, MYDICAR, and CAP-1002) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends, and Forecast 2014 - 2020.”

For the report, the global dilated cardiomyopathy therapeutics market is segmented as follows:

Dilated Cardiomyopathy Therapeutics Market, by Drug Class

Aldosterone antagonists
Angiotensin-converting enzyme (ACE) inhibitors
Angiotensin II receptor blockers (ARBs)
Beta-blockers
Dilated Cardiomyopathy Therapeutics Market, by Pipeline Drugs

ARRY-797
ixCELL-DCM
MYDICAR
OR-1
CAP-1002
Dilated Cardiomyopathy Therapeutics Market, by Geography

North America
Europe
Asia Pacific
Rest of the World (RoW)
 

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Dilated Cardiomyopathy Therapeutics Market: Increasing Prevalence of Congestive Heart Failure Fuels Growth, finds TMR here

News-ID: 668551 • Views: 337

More Releases from Transparency Market Research

Latest TMR Report Explores Impact of COVID-19 Outbreak on Industrial Air Compres …
Industrial Air Compressor Market: Introduction The global industrial air compressor market is anticipated to reach US$ 26.6 Bn by 2030. The industrial air compressor market is projected to expand at a CAGR of ~4% from 2020 to 2030 based on revenue. According to the report, Asia Pacific was a significant contributor to the industrial air compressor market in terms of revenue in 2019. The prominent market share of the region is
Automotive Head-up Display (HUD) Market is projected to surpass US$ 4.7 Bn by 20 …
Automotive Head-up Display (HUD) Market: Introduction According to the report, the global automotive head-up display (HUD) market is projected to surpass US$ 4.7 Bn by 2030, expanding at a CAGR of ~22% during the forecast period. Rise in demand for comfort and safety features in vehicles is likely to boost the automotive head-up display (HUD) market across the globe. Increase in preference for utility vehicles and luxury vehicles, in conjunction with
Understanding Impact of COVID-19 on Retail Clinics Market
Global Retail Clinics Market – Overview Retail clinics are the ones that provide primary healthcare services across departmental stores, supermarkets, and retail stores. These clinics have a registration desk, a waiting area, washroom, a couple of examination rooms, and a small desk for reception. These retail clinics are gaining immense popularity as they are highly beneficial for public health, easily accessible, and also help in reducing the pressure on public healthcare
Potential Impact of COVID-19 on Self-tanning Products Market
Self-tanning Products Market: Introduction Transparency Market Research delivers key insights on the global self-tanning products market. In terms of revenue, the global self-tanning products market is estimated to expand at a CAGR of ~6% during the forecast period, owing to numerous factors regarding which TMR offers thorough insights and forecasts in the global self-tanning products market report. Obtain Report Details @ https://www.transparencymarketresearch.com/self-tanning-products-market.html In terms of type, the self-tanning products market has been segmented

All 5 Releases


More Releases for Dilated

Global Dilated Cardiomyopathy Market Insights, Forecast
Dilated Cardiomyopathy (DCM) refers to the cardiac hypertrophy, cannot effectively pump blood. Dilated Cardiomyopathy (DCM) is due to genetic or other disease caused by a heart disease, it respectively affect the ventricles of the heart and heart, the inferior vena chamber and the upper Chambers of the heart. The global Dilated Cardiomyopathy market is valued at 180 million US$ in 2018 and will reach 290 million US$ by the end
Dilated Cardiomyopathy Market Opportunity Analysis, 2026 – 2026
Dilated cardiomyopathy (DCM) is a condition in which the heart gets enlarged and is not able to efficiently pump blood. The reduced heart function can affect the functioning of other organs such as lungs, liver, and kidney. The heart muscles begin to dilate (stretches), which result in thinning and increased area of the chamber, further it spreads to the right ventricle and atria’s. As the heart chambers dilate, heart muscles
Dilated Cardiomyopathy Market – Global Industry Insights,2025
Dilated cardiomyopathy (DCM) is a condition in which the heart gets enlarged and is not able to efficiently pump blood. The reduced heart function can affect the functioning of other organs such as lungs, liver, and kidney. The heart muscles begin to dilate (stretches), which result in thinning and increased area of the chamber, further it spreads to the right ventricle and atria’s. As the heart chambers dilate, heart muscles
Dilated Cardiomyopathy - Pipeline Review, H1 2017
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Dilated Cardiomyopathy - Pipeline Review, H1 2017, provides an overview of the Dilated Cardiomyopathy (Cardiovascular) pipeline landscape. Dilated cardiomyopathy (DCM) is a condition in which the heart's ability to pump blood is decreased because the heart's main pumping chamber, the left ventricle, is enlarged and weakened. Symptoms include Fatigue and weakness, Shortness of breath (dyspnea), lightheadedness, dizziness or fainting, persistent cough or wheezing,
Dilated Cardiomyopathy Therapeutics Market Research Report Forecast
A new market research report has been recently published by Transparency market research, a leading market intelligence firm. The research report, titled “Dilated Cardiomyopathy Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020”, presents a market overview, market drivers, opportunities, challenges, product segmentation, and competitive landscape. The research report also features inputs and recommendations from industry experts and professionals to help the
Dilated Cardiomyopathy Therapeutics Market Company Analysis and Forecast to 2020
Dilated cardiomyopathy (DCM) is a significant cause of heart failure and a leading indication for heart transplant among children and adults across the globe. This condition is characterized by enlargement of ventricular chamber, thinning of heart walls and inability to sufficiently pump blood throughout the body. Dilated cardiomyopathy can develop at any age but is more common among people aged between 20 years to 60 years. Genetic inheritance is found